Skip to main content
Premium Trial:

Request an Annual Quote

Next Generation of Jobs Fund- Biopharmaceutical Investment Program, Sanofi Pasteur, University of Maryland School of Pharmacy, Indiana Economic Development Corp., Dormir, Aileron Therapeutics, Bingham Economic Development Corp., US Department of Energy, I

Sanofi Pasteur Plans $99.6M Vaccine Research Facility at Toronto’s Connaught Campus
Sanofi Pasteur has unveiled plans for a $100 million CAD ($99.6 million) vaccine research facility at the company's Connaught Campus in North Toronto, Ontario.
The project includes the construction of an $80 million CAD ($79.7 million) facility, the purchase of specialized research & development equipment, and the support of R&D jobs over the next five years. Construction of the 165,000 square-foot facility will begin in 2008 and is projected to be ready for occupancy in 2010.
The building will include a heat reclamation system to reduce heating and cooling needs; insulated building panels and glass structure intended to reduce energy consumption, and energy-efficient lighting. The company’s natural gas-powered cogeneration system will serve the new facility's electrical and steam requirements.
The Government of Ontario is subsidizing the project by awarding Sanofi Pasteur $13.9 million CAD ($13.8 million) through the Biopharmaceutical Investment Program. The BIP is administered by the Ministry of Research and Innovation and is part of the government's Next Generation of Jobs Fund.
With the new research facility, Sanofi Pasteur will have spent more than $300 million CAD ($298.8) in capital expansion at Connaught Campus since 2000. Sanofi Pasteur is the vaccines division of French-owned Sanofi-Aventis.

Maryland OKs $62M New Building for UM School of Pharmacy
Maryland’s new $31.2 billion state budget for the fiscal year that begins July 1 includes $62 million toward construction of a building that will serve as an addition to Pharmacy Hall at the University of Maryland School of Pharmacy.
The 92,635-square-foot, seven-story building will include lecture halls wired for computers and distance-learning technology, a new patient interaction laboratory, and four floors of space dedicated to clinical and translational research in pharmacogenetics, nanomedicine, and drug discovery. The new space will be an addition to the existing, 25-year-old Pharmacy Hall, with a glass pavilion connecting the two buildings. The building will incorporate energy-efficiency features designed to secure a silver Leadership in Energy and Environmental Design, or LEED, rating.
UM said the new addition help help it accommodate a growing enrollment of pharmacy majors. The school has 120 students per class, and last fall the university opened a center accommodating 40 more students per class within the Universities at Shady Grove, in Montgomery County.
Ten years in the planning, the project is projected to open for the fall 2010 semester.

Parent of Medical Equipment Company Adds 160 Jobs in Carmel, Ind., HQ Expansion
Dormir, the parent of sleep center development and management company MD Sleep and medical equipment maker CardioSom, will undertake a $2.5 million expansion of its corporate headquarters in the Indianapolis suburb of Carmel, Ind., creating more than 160 new jobs.

The privately held manager of physician- and hospital-owned sleep disorder centers, which also sells durable medical equipment at stores in 14 states, will begin this quarter to hire new managers, information technology specialists, billing technicians, sales/marketing representatives, human resources professionals and accountants. Those staffers will join a company workforce of 150 people nationwide, of which 47 are based at the Carmel HQ.

In return for the new jobs, the Hoosier State’s economic development agency, Indiana Economic Development Corp., offered Dormir LLC up to $1.25 million in performance-based tax credits and up to $100,000 in training grants based on the company's job creation plans. The city of Carmel will consider property tax abatement for the expansion.
Dormir will also upgrade its computer hardware and software. Dormir operates facilities in Greenwood, Indianapolis, Noblesville, Kokomo and Ft. Wayne, and will open new centers in Anderson, Marion, and South Bend.
"The geographic location, airport expansion, affordable housing costs and quality of life make central Indiana very appealing to our workforce,” Tim Miller, chief executive officer of Dormir, said in an IEDC press release announcing the deal.

Cambridge, Mass., Biotech Plans New Facility, Staff Expansion With $10M Private Placement
Aileron Therapeutics said it will use the proceeds of a $10 million private placement it has raised to open a 10,000-square-foot “stapled peptide” research facility at Riverside Technology Center (840 Memorial Drive) in Cambridge, Mass., as well as add drug-discovery professionals to its 14-person staff.
Aileron, which focuses on peptide-based treatments for cancer and other diseases, has doubled to $20 million the amount of private capital raised since it was established in 2001. Novartis Venture Fund and Apple Tree Partners, two previous investors with offices in Cambridge, led the latest private placement.

Vying With Idaho for Ethanol Plant, Canada Rolls Out New Incentives
New economic incentives by Canada may prompt a Canadian biotech company to choose its native country over Idaho as the site of a planned new cellulosic ethanol plant, the Post-Register of Idaho Falls, Idaho, reported.
Iogen is considering Saskatchewan as well as a site near Shelley, Idaho, for the project, projected to cost $350 million in 2006. Iogen had been leaning to the Idaho site, given its proximity to farmers already under contract to provide the wheat and barley straw, corn stover, and switch grass the plant would use to produce ethanol.
But last month, Canada announced it would spend $500 million in government funding for projects to build next-generation biofuels plants nationwide. If Iogen chooses Canada and takes a share of that incentive money, the company would lose out on an $80 million grant and loan guarantees promised by the US Department of Energy. One factor in Canada’s favor, however, is that Iogen has had a pilot plant near Ottawa since 2004.
Two officials told the Post-Register they remained confident Iogen would choose Idaho — Brandon Bird, executive director of the Bingham Economic Development Corp., and a spokesman for US Sen. Larry Craig (R-Idaho), who visited Iogen’s pilot plant earlier this month.
The plant is projected to generate 100 permanent jobs and 200 temporary construction jobs — as well as produce 18 million gallons of ethanol a year, boosting area farm revenues by an estimated $16 an acre.
Bird, however, said Iogen is hesitating to commit to this project without assurances it will receive the US loan guarantees and grant: "They want them to go hand-in-hand.”

Citing Forest City Progress, Baltimore Development Corp. Eyes New Development Nearby
Citing the progress achieved by Science + Technology Park at Johns Hopkins by Forest City Science + Technology Group and other redevelopment projects in the East Baltimore section, [BRN, April 14] — the city of Baltimore is pursuing a strategy to revive the rundown OldTown Mall.
The public-private nonprofit Baltimore Development Corp. has begun acquiring non-historic properties within the mostly-vacant mall, and has issued a formal request for proposals, available here with registration, by developers interested in constructing new housing and retail space, the Baltimore Sun reported. Deadline for responses is June 4 at 5 p.m.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.